Copenhagen, 10 November 2009 - NeuroSearch's (NEUR.CO) Q3 interim report 2009 will be on the agenda of a Board meeting scheduled for 16 November 2009 and be released immediately hereafter. On the same day, a teleconference will be held at 3 pm Copenhagen time (2 pm London time, 9 am New York time) where Flemming Pedersen, CEO, Anita Milland, Vice President & CFO and Hanne Leth Hillman, Vice President & Director of Investor & Capital Market Relations, will present the Q3 interim report 2009 and answer questions. The teleconference will be conducted in English and the telephone number is +44 (0) 20 7162 0077. The corresponding PowerPoint presentation will be available at www.neurosearch.com. Contact person: Hanne Leth Hillman, Vice President, Director of Investor & Capital Market Relations, telephone: +45 4460 8212 or +45 4017 5103 About NeuroSearch - Company profile NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S. The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and GlaxoSmithKline (GSK), and a license collaboration with Abbott. The drug pipeline comprises eight clinical (Phase I-III) development programmes: Huntexil® (pridopidine) for Huntington's disease (Phase III), tesofensine for obesity (ready for Phase III), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias in Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety (Phase I) and NSD-721 for social anxiety disorder (Phase I) in partnership with GSK. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.
NeuroSearch announces the date for the company's Q3 interim report 2009 and a related telephone conference
| Source: NTG Nordic Transport Group A/S